Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors

Journal of Gene Medicine

Volumn 6, Issue 8, 2004, Pages 857-868

  Liu, Yongqing ^a   Saxena, Anurag ^a   Zheng, Changyu ^b   Carlsen, Svein ^a   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Saskatoon Cancer Center   (Canada)

Author keywords

Antitumor immunity; Cytotoxic T lymphocyte; Engineered dendritic cell vaccine; Gene therapy; TNF

Indexed keywords

ADENOVIRUS VECTOR; DENDRITIC CELL VACCINE; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENETIC ENGINEERING; IMMUNE RESPONSE; IMMUNOSTIMULATION; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME; VACCINATION; VIRAL GENE THERAPY;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; GENE THERAPY; HUMANS; INJECTIONS, SUBCUTANEOUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TRANSGENES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; ANIMALIA;

EID: 12244270756     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.576     Document Type: Article

References (55)

1. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72: 3666-3670.
2. Talmadge JE, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988; 48: 544-550.
3. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
4. Mueller H. Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 1998; 54: 1291-1298.
5. Asher A, Mule JJ, Reichert CM, et al. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963-974.
6. Renard N, Lienard D, Lespagnard L, et al. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 1994; 57: 656-663.
7. Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995; 55]: 4824-4829.
8. Feinberg B, Kurzrock R, Talpaz M, et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328-1334.
9. Moritz T, Niederle N, Baumann J, et al. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother 1989; 29: 144-150.
10. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80: 1039-1044.
11. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
12. Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995; 13: 264-273.
13. Cao G, Kuriyama S, Du P, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology 1997; 112: 501-510.
14. Koshita Y, Lu Y, Fujii S, et al. Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer 1995; 63: 130-135.
15. Xiang J, Qi Y, Chen Y. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF. Cancer Gene Ther 1997; 4: 353-358.
16. Marr RA, Addison CL, Snider D, et al. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther 1997; 4: 1181-1188.
17. Marr RA, Hitt M, Muller WJ, et al. Tumour therapy in mice using adenovirus vectors expressing human TNF-α. Int J Oncol 1998; 12: 509-515.
18. Marr RA, Hitt M, Gauldie J, et al. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene Ther 1999; 6: 465-474.
19. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14: 49-57.
20. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
21. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
22. Steinman R, Witmer-Pack M, Inaba K, et al. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329: 1-10.
23. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
24. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-332.
25. Nair S, Snyder D, Rouse B, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706-715.
26. Curiel-Lewandrowski C, Mahnke K, Labeur M, et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 174-183.
27. Liu Y, Huang H, Chen Z, et al. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytotoxic T and natural killer cell cytotoxicities and antitumor immunity. J Gene Med 2003; 5: 668-680.
28. Liu Y, Zhang X, Zhang W, et al. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8 cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther 2002; 9: 202-208.
29. Zheng W, Chen Z, Li F, et al. Tumor necrosis factor transgene-expressing dendritic cells undergo augmented cellular maturation and induce more robust T-cell activation and antitumor immunity than DCs generated in recombinant TNF. Immunology 2003; 108: 177-188.
30. Hsieh CL, Pang VF, Chen DS, et al. Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. Hum Gene Ther 1997; 8: 1843-1854.
31. Perez-Diez A, Spiess PJ, Restifo NP, et al. Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002; 168: 338-347.
32. Chen Z, Moyana T, Sexena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93: 539-548.
33. Hogquist K, Jameson A, Heath S, et al. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27.
34. Mandelboim O, Berke M, Fridkin M, et al. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 67-72.
35. Xiang J, Moyana T. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J Interferon Cytokine Res 2000; 20: 349-354.
36. Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch Dermatol Res 1996; 289: 1-8.
37. Caux C, Dezutter-Dambuyant C, Schmitt D, et al. GMCSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-269.
38. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and Prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135 -3142.
39. Labeur M, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 168-175.
40. Rieser C, Bock G, Klocker H, et al. Prostaglandin Ea and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 1997; 186: 1603-1608.
41. Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic antitumor immune responses in vivo. J Immunol 2000; 165: 6278-6286.
42. Cumberbatch M, Kimber I. Tumor necrosis factor-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 1995; 84: 31-35.
43. Brody S, Jaffee H, Han S, et al. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 1994; 5: 437-447.
44. Chen S, Shine H, Goodman J, et al. Gene therapy for brain tumor-regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994; 91: 3054-3057.
45. Bett A, Haddara W, Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early region 1 and 3. Proc Natl Acad Sci U S A 1994; 91: 8802-8806.
46. Sarraf C. Tumor necrosis factor and cell death in tumors. Int J Oncol 1994; 5: 1333-1339.
47. Tracey K, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
48. Ruegg C, Yilmaz A, Bieler B, et al. Evidence for the involvement of endothelial cell integrin alpha beta 3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-414.
49. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196.
50. Van Ostade X, Vandenabeele P, Everaerdt B, et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993; 361: 266-269.
51. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
52. Mauceri HJ, Hanna NN, Wayne JD, et al. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996; 56: 4311-4314.
53. Muenchen HJ, Lin DL, Walsh MA, et al. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res 2000; 6: 1969-1977.
54. Bakker TR, Reed D, Renno T, et al. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis. Int J Cancer 1999; 80: 320-323.
55. Shatrov VA, Ameyar M, Bouquet C, et al. Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state. Int J Cancer 2000; 85: 93-97.